185 related articles for article (PubMed ID: 35676000)
21. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China.
Qi XP; Chen XL; Ma JM; Du ZF; Fei J; Yang CP; Cheng J; Song QZ; Han JS; Jin HY; Chen ZG; Wang JQ; Yang YP; Ying RB; Liu WT; Zhao Y; Chen CY; Jiang HL; Ke HP; Zhang XN
Thyroid; 2012 Dec; 22(12):1257-65. PubMed ID: 23210566
[TBL] [Abstract][Full Text] [Related]
22. Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case.
Hibi Y; Ohye T; Ogawa K; Shimizu Y; Shibata M; Kagawa C; Mizuno Y; Uchino S; Kosugi S; Kurahashi H; Iwase K
Surg Today; 2014 Nov; 44(11):2195-200. PubMed ID: 24449023
[TBL] [Abstract][Full Text] [Related]
23. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).
Lee JY; Kim SY; Jo KH; Mo EY; Kim ES; Kim HS; Han JH; Moon SD
Korean J Intern Med; 2022 Mar; 37(2):398-410. PubMed ID: 34905813
[TBL] [Abstract][Full Text] [Related]
25. A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A.
Bethanis S; Koutsodontis G; Palouka T; Avgoustis C; Yannoukakos D; Bei T; Papadopoulos S; Linos D; Tsagarakis S
Hormones (Athens); 2007; 6(2):152-6. PubMed ID: 17704047
[TBL] [Abstract][Full Text] [Related]
26. Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: implications for screening.
Rowland KJ; Chernock RD; Moley JF
J Surg Oncol; 2013 Sep; 108(4):203-6. PubMed ID: 23868299
[TBL] [Abstract][Full Text] [Related]
27. Clinical spectrum of MEN2A in a large family caused by the infrequent RET mutation Cys609Phe.
Oriola J; Biarnes J; Hernandez C; Simó R
Clin Genet; 2013 Apr; 83(4):384-7. PubMed ID: 22734615
[TBL] [Abstract][Full Text] [Related]
28. [The trends in early precision diagnosis and treatment strategies of multiple endocrine neoplasia type 2].
Qi XP; Jin B
Zhonghua Wai Ke Za Zhi; 2022 Nov; 60(11):973-980. PubMed ID: 36323578
[TBL] [Abstract][Full Text] [Related]
29. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
30. [Multiple endocrine neoplasia type IIa (MEN2A)].
Hashizume K; Suzuki S; Shigematsu S; Takeda T
Nihon Rinsho; 2006 Sep; Suppl 3():337-42. PubMed ID: 17022559
[No Abstract] [Full Text] [Related]
31. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2.
Toledo SP; dos Santos MA; Toledo Rde A; Lourenço DM
Clinics (Sao Paulo); 2006 Feb; 61(1):59-70. PubMed ID: 16532227
[TBL] [Abstract][Full Text] [Related]
32. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.
Raue F; Frank-Raue K
Hormones (Athens); 2009; 8(1):23-8. PubMed ID: 19269918
[TBL] [Abstract][Full Text] [Related]
33. Multiple endocrine neoplasia type 2.
Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
[TBL] [Abstract][Full Text] [Related]
34. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
[TBL] [Abstract][Full Text] [Related]
35. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family.
Qi XP; Ma JM; Du ZF; Ying RB; Fei J; Jin HY; Han JS; Wang JQ; Chen XL; Chen CY; Liu WT; Lu JJ; Zhang JG; Zhang XN
PLoS One; 2011; 6(5):e20353. PubMed ID: 21655256
[TBL] [Abstract][Full Text] [Related]
36. Catecholamine crisis as a first manifestation of familial bilateral pheochromocytoma caused by RET proto-oncogene mutation in codon C 634R.
Zwolak A; Rudzki G; Świrska J; Dudzińska M; Daniluk J; Tarach J
Endokrynol Pol; 2015; 66(5):462-8. PubMed ID: 26457501
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.
Mian C; Barollo S; Zambonin L; Pennelli G; Bernante P; Pelizzo MR; Nacamulli D; Mantero F; Girelli ME; Opocher G
Fam Cancer; 2009; 8(4):379-82. PubMed ID: 19475497
[TBL] [Abstract][Full Text] [Related]
38. 5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.
Li SY; Ding YQ; Si YL; Ye MJ; Xu CM; Qi XP
Front Endocrinol (Lausanne); 2020; 11():543246. PubMed ID: 33071967
[TBL] [Abstract][Full Text] [Related]
39. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic correlation between RET proto-oncogene mutation, imaging techniques, biochemical markers and morphological examination in MEN2A syndrome: case report and literature review.
Sovrea AS; Dronca E; Galatâr M; Radian S; Vornicescu C; Georgescu C
Rom J Morphol Embryol; 2014; 55(2):389-400. PubMed ID: 24969991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
